News
Early intensive treatment of MS may benefit patients
Real-world population-based cohort study finds better outcomes at 5 years with first-line treatment with a high-efficacy therapy.
Conference Coverage
Autologous Hematopoietic Stem Cells May Treat Aggressive MS Effectively
BERLIN—Autologous hematopoietic stem cell transplantation (HSCT) could prevent disease activity and promote functional...
Conference Coverage
Interferon Beta May Not Affect Pregnancy Outcomes in MS
BERLIN—European registry data do not support the hypothesis that exposure to interferon beta before conception or during...
News
Daclizumab beta may be superior to interferon beta on MS disability progression
A post hoc analysis indicates that daclizumab beta has superior efficacy, compared with interferon beta-1a, regardless of patients’ baseline...
News
Does rituximab delay disability progression in patients with secondary progressive MS?
Patients with secondary progressive MS who are treated with rituximab off label may accrue less disability during follow-up, compared with matched...
News
Integrated analysis suggests cladribine’s safety in MS
Cladribine is not associated with an increased risk of infections or malignancy, and treatment-induced lymphopenia is transient.
News
Food allergies linked to increased MS relapses, lesions
Patients with food allergies had more MS relapses and greater odds of further nerve damage.
Conference Coverage
Real-world data reveal long-lasting effects achieved with RRMS treatments
BERLIN –
Article
Virus-Specific T-Cell Infusions May Resolve Progressive Multifocal Leukoencephalopathy
Infusion of allogeneic BK virus-specific T cells may be an effective treatment for patients with progressive multifocal...
Conference Coverage
Dietary sodium still in play as a potential MS risk factor
BERLIN – High-salt diets decimate Lactobacillus species, with downstream immune effects.
Conference Coverage
Breastfeeding with MS: Good for mom, too
News
Stroke, arterial dissection events reported with Lemtrada, FDA says
Rare but serious events described in multiple sclerosis patients given alemtuzumab (Lemtrada) prompts new warning.
Conference Coverage
Fatigue in MS: Common, often profound, tough to treat
BERLIN – Cognitive behavioral therapy carries the best evidence to treat MS-related fatigue.
Conference Coverage
Particular lesions early after CIS predict long-term MS disability
Article
Panel Provides Recommendations for Managing Cognitive Changes in MS
The National Multiple Sclerosis (MS) Society has developed recommendations for the identification and management of...
Conference Coverage
MS disease activity returns in one-third after fingolimod withdrawal
BERLIN – Risk factors for higher disease activity include younger age at diagnosis, shorter disease duration, and stopping more than 2 months...
Conference Coverage
-
Autologous Hematopoietic Stem Cells May Treat Aggressive MS Effectively -
Interferon Beta May Not Affect Pregnancy Outcomes in MS -
-
-
Multimedia
Question 1 of 5